Prosight Management’s Q32 Bio QTTB Stock Holding History

Prosight Management’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-8,517	Closed	-$2.77M	–	44
2019 Q3	$2.77M	Sell	8,517 -11,986	-58%	-$4.07M	1.54%	21
2019 Q2	$7.22M	Buy	+20,503	New	+$8.06M	3.64%	12

Other funds holding QTTB

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management's QTTB Position: Q4 2019 in Review

Prosight Management sold out of Q32 Bio (QTTB) in Q4 2019, closing a stake of 8,517 shares — an estimated $2.77M sold.

Prosight Management first reported a position in QTTB in Q2 2019 and held it in 2 quarters. The position peaked at $7.22M in Q2 2019. 86 funds tracked by Wall St. Rank hold QTTB as of Q4 2019.

Prosight Management reported no remaining Q32 Bio position as of Q4 2019 after selling out during the quarter.
Prosight Management sold 8,517 Q32 Bio shares in Q4 2019, an estimated $2.77M.
Prosight Management first reported a position in Q32 Bio in Q2 2019 and held it in 2 quarters.
Prosight Management's Q32 Bio position peaked at $7.22M in Q2 2019.
86 funds tracked by Wall St. Rank held Q32 Bio as of Q4 2019.

Based on Prosight Management's 13F filing for Q4 2019, filed 14 Feb 2020.